Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
PKD1 antisense RNA 1 (PKD1-AS1), also known as LUCRC (LncRNA Upregulated in Colorectal Cancer), is a long non-coding RNA transcribed antisense to the PKD1 gene locus. PKD1-AS1 is notably upregulated in colorectal cancer, where it has been shown to promote cell growth and tumorigenesis, primarily through modulation of pathways associated with endoplasmic reticulum stress response[6]. As a lncRNA, PKD1-AS1 does not encode a protein but can regulate gene expression at the transcriptional or post-transcriptional level. Its close association with both colorectal cancer and the PKD1 gene locus (associated with polycystic kidney disease) suggests possible roles in gene regulation and disease pathophysiology. PKD1-AS1 is being investigated as a potential biomarker for colorectal cancer diagnosis and prognosis, but it is not a classical therapeutic target such as a receptor, enzyme, or ion channel[6][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on PKD1 antisense RNA 1 (PKD1-AS1).